WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that the company will present preclinical data related to PEN-866 at the 2018 American Association for Cancer Research (AACR) Annual Meeting, occurring April 14-18, 2018 in Chicago, IL. PEN-866 is a miniature drug conjugate designed to treat patients with solid tumor types known to be sensitive to topoisomerase 1 inhibitors such as SN-38, the payload of PEN-866. The presentation will address the combination of PEN-866 with PARP inhibitors in models of ovarian cancer, lung cancer and colorectal cancer.
Details of the poster presentation are as follows:
|
Title: |
Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy | ||
|
Date: |
April 18, 2018 | ||
|
Time: |
8:00 AM – 12:00 PM CT | ||
|
Location: |
Section 37, McCormick Place North/South, Chicago, IL | ||
About PEN-866
PEN-866 exploits the activation of Heat Shock
Protein 90 (HSP90) in tumors to accumulate and release its potent
anti-cancer payload, SN-38. PEN-866 is a miniature conjugate that
comprises a small molecule, HSP90-targeting ligand linked to SN-38, the
active metabolite of irinotecan. The conjugate accumulates and is
retained in tumors, and by way of a sustained release of SN-38, causes
prolonged DNA damage and tumor regressions in multiple patient-derived
and other xenograft tumor models.
About Pentarins™
Tarveda is developing Pentarins™, potent
and selective miniature drug conjugates with high affinity for specific
cell surface and intracellular targets. Pentarins are engineered to bind
to their tumor cell targets and provide sustained release of their
potent therapeutic payloads deep into solid tumor tissue. Comprised of a
targeting ligand conjugated to a potent cancer cell killing agent
through a tuned chemical linker, Pentarins are designed to overcome the
deficits of both larger antibody drug conjugates and small molecules
that limit their therapeutic effectiveness against solid tumors.
Together, the components of Tarveda’s Pentarins have distinct, yet
synergistic, anticancer attributes: the small size of Pentarins allows
for rapid and deep penetration into the tumor tissue, the ligand’s
targeting ability allows for specific binding and retention in tumor
cells, and the chemical linker is tuned to optimize the release of the
potent, cell killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc.
discovers and develops Pentarins™, a new class of potent and selective
miniature drug conjugates with enhanced targeting capabilities for the
treatment of a wide range of solid tumor cancers. Tarveda’s lead
Pentarin drug candidate, PEN-221, is a miniature drug conjugate that
targets the somatostatin receptor 2 (SSTR2) for treatment of patients
with neuroendocrine, prostate, small cell lung and other cancers that
express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2
conjugated to the potent cytotoxic payload, DM1, through a tuned
cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug
conjugate platform with lead drug candidate PEN-866, which is a
miniature drug conjugate that selectively binds to the intracellular
target, Heat Shock Protein 90 (HSP90), and is linked to the payload
SN-38, the highly potent active metabolite of irinotecan. Tarveda’s
strategy includes developing its own proprietary Pentarins as well as
applying the Pentarin platform to enhance the effectiveness of the
targeting moieties and novel payloads of pharmaceutical collaborators. www.tarveda.com
